RxDoctor Payments Data

Chitra Venkatasubramanian, MD

Vascular Neurology · Stanford, CANPI 1912930678

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $239,876 of the $260,059 with a category attached, or 92.2%. 10 manufacturers reported payments, led by Ceribell, Inc. at 49.6% of the total. Among vascular neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$260,059in general payments, 2019–2025

Across 168 payments — averaging $1547.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ceribell, Inc.$129K
  • AbbVie$111K
  • Portola Pharmaceuticals, LLC$8K
  • AstraZeneca$6K
  • Alnylam Pharmaceuticals Inc.$3K
  • Biogen$2K
  • plus $618 from 4 others
$597,472in research payments, 2019–2025

Across 58 payments — averaging $10,301 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$205K
  • Novartis$169K
  • Alnylam Pharmaceuticals Inc.$110K
  • C. R. Bard, Inc. & Subsidiaries$103K
  • AbbVie$10K

What the payments were for

  • Consulting fees$239,87692%
  • Speaking & faculty fees$7,6003%
  • Travel & lodging$10,0714%
  • Food & beverage$2,4851%
  • Education$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$260,059 in reported general payments places this provider in the 95th percentile of 58 vascular neurology providers in California.

See all vascular neurology providers in California

Medicare billing

Part B allowed, 2024
$72,046
Medicare patients
143
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular neurology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →